Medical Weight Loss Spencerville Maryland

Clinical studies show that patients using FDA-approved medications like semaglutide typically lose 15-20% of their starting body weight over 68 weeks when combined with lifestyle modifications. Tirzepatide has shown even greater results, with up to 22.5% weight loss in clinical trials. Individual results vary based on factors like starting weight, adherence to treatment, and overall health status. Dr. Nawrocki will discuss realistic expectations based on your specific situation during your consultation.

The most common side effects of GLP-1 medications include mild nausea, occasional vomiting, diarrhea, and constipation, particularly when starting treatment or increasing doses. These effects typically decrease as your body adjusts to the medication, usually within 2-4 weeks. Dr. Nawrocki provides detailed guidance on managing any side effects and can adjust your treatment plan if needed to ensure your comfort throughout the process.

Medical weight loss is typically recommended for adults with a BMI of 30 or higher, or those with a BMI of 27 or higher who have weight-related health conditions like diabetes, high blood pressure, or sleep apnea. During your consultation, Dr. Nawrocki will evaluate your medical history, current health status, and weight loss goals to determine if medical weight loss is appropriate for you.

The duration of treatment varies for each patient based on their weight loss goals and response to medication. Many patients continue treatment for 12-18 months to achieve their target weight, then work with Dr. Nawrocki to develop a maintenance plan. Some patients benefit from long-term treatment to maintain their weight loss results, similar to how other chronic conditions are managed.

Insurance coverage for medical weight loss varies significantly between plans and providers. Some insurance plans cover consultations and medications for patients who meet specific medical criteria, particularly those with a BMI of 30+ or 27+ with weight-related health conditions. During your consultation, our team can provide information about your options and help you understand the investment in your health and wellness.

Weight regain is possible if medication is discontinued without implementing strong lifestyle maintenance strategies. Studies show that continuing medication or having a structured maintenance plan helps patients maintain their weight loss long-term. Dr. Nawrocki works with each patient to develop personalized strategies for maintaining results, whether continuing medication or implementing lifestyle-based maintenance approaches.

Many patients begin noticing reduced appetite and early weight loss within the first 2-4 weeks of treatment. Significant weight loss typically becomes apparent within 8-12 weeks as medication reaches therapeutic levels and lifestyle changes take effect. Studies show patients can lose an average of 6% of their weight by week 12 and 12% by week 28. Dr. Nawrocki monitors your progress closely and can adjust your treatment plan to optimize your results throughout your journey.

Both are FDA-approved GLP-1 receptor agonists for weight loss, but tirzepatide (Mounjaro/Zepbound) has a dual mechanism of action, activating both GLP-1 and GIP receptors. Recent clinical trials show tirzepatide may be more effective, with patients losing an average of 22.8% of body weight compared to 15% with semaglutide. Dr. Nawrocki will help determine which medication is most appropriate based on your medical history, goals, and individual response to treatment.